| Literature DB >> 31851927 |
Gérald Kénanian1, Claire Morvan1, Antonin Weckel2, Amit Pathania1, Jamila Anba-Mondoloni1, David Halpern1, Marine Gaillard2, Audrey Solgadi3, Laetitia Dupont1, Céline Henry4, Claire Poyart5, Agnès Fouet2, Gilles Lamberet1, Karine Gloux1, Alexandra Gruss6.
Abstract
The essentiality of fatty acid synthesis (FASII) products in the human pathogen Staphylococcus aureus is the underlying rationale for FASII-targeted antimicrobial drug design. Reports of anti-FASII efficacy in animals support this choice. However, restricted test conditions used previously led us to investigate this postulate in a broader, host-relevant context. We report that S. aureus rapidly adapts to FASII antibiotics without FASII mutations when exposed to host environments. FASII antibiotic administration upon signs of infection, rather than just after inoculation as commonly practiced, fails to eliminate S. aureus in a septicemia model. In vitro, serum lowers S. aureus membrane stress, leading to a greater retention of the substrates required for environmental fatty acid (eFA) utilization: eFAs and the acyl carrier protein. In this condition, eFA occupies both phospholipid positions, regardless of anti-FASII selection. Our results identify S. aureus membrane plasticity in host environments as a main limitation for using FASII antibiotics in monotherapeutic treatments.Entities:
Keywords: AFN-1252; antibiotic resistance; conditional antibiotic adaptation; fatty acid stress; firmicute pathogens; infection; membrane phospholipids; treatment failure; triclosan
Mesh:
Substances:
Year: 2019 PMID: 31851927 DOI: 10.1016/j.celrep.2019.11.071
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423